Acute Stroke, Ischemic Stroke
Conditions
Keywords
acute ischemic stroke, noncoding RNA, clinical significance, outcome
Brief summary
AISRNA is to analyze the expression pattern of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA) by next-generation sequencing in patients with acute ischemic stroke and healthy control. The candidate circRNA/miRNA/lncRNA will be verified as biomarkers for the detection and prognosis of acute ischemic stroke.
Detailed description
Noncoding RNAs have been highlighted to be involved in the pathological process of ischemic stroke (IS). The purpose of this protocol will investigate the expression pattern of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA) by next-generation sequencing in patients with acute ischemic stroke and healthy control. The candidate circRNA/miRNA/lncRNA will be verified as biomarkers for the detection and prognosis of acute ischemic stroke. Distinctive expression patterns of circRNA/miRNA/lncRNA will be identified by the next-generation sequencing and individual quantitative real time polymerase chain reaction (qRT-PCR). A diagnostic or predictive model will be established using logistic regression. The panel of these altered ncRNAs may be associated with acute IS and could serve as a novel diagnostic or predictive method.
Interventions
GENETICSequencing of circRNA/miRNA/lncRNA
Next generation sequencing of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA)
Sponsors
Nanjing First Hospital, Nanjing Medical University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Aged 18 years or older * Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan * Within 72 hours of symptom onset * Good performance status * Signed an approved informed consents
Exclusion criteria
-a history of hemorrhagic infarction, chronic kidney/liver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Differential expression pattern of circRNA/miRNA/lncRNA | 90 days | Differential expression pattern of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA) will be compared between AIS group and HC group, thus candidate circRNA/miRNA/lncRNA will be verified as biomarkers for the detection and prognosis of AIS. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prognostic value of circRNA/miRNA/lncRNA in acute ischemic stroke | 90 days | The prognosis of AIS patients will be analyzed between differential expressed candidate miRNA/lncRNA after they have completed the systematic therapy. |
| Correlation of circRNA/miRNA/lncRNA and inflammatory factors in acute ischemic stroke | 7 days | Correlation of circRNA/miRNA/lncRNA and inflammatory factors on admission will be explored in acute ischemic stroke. |
| Correlation of circRNA/miRNA/lncRNA and stroke-associated infection | 30 days | Correlation of circRNA/miRNA/lncRNA and stroke-associated infection will be explored in acute ischemic stroke. |
| Dynamic changes of circRNA/miRNA/lncRNA during the follow-up period | 90 days | Dynamic changes of circRNA/miRNA/lncRNA will be explored before and after endovascular therapy |
Countries
China
Contacts
CONTACTJunshan Zhou, M.D.
CONTACTQiwen Deng, M.D.
STUDY_CHAIRJunshan Zhou, Professor
Nanjing Medical University
Outcome results
None listed